Ameritas Investment Partners Inc. Has $18.99 Million Stock Position in Eli Lilly and Company $LLY

Ameritas Investment Partners Inc. lowered its stake in Eli Lilly and Company (NYSE:LLY) by 6.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 17,673 shares of the company’s stock after selling 1,313 shares during the period. Eli Lilly and Company makes up 0.6% of Ameritas Investment Partners Inc.’s investment portfolio, making the stock its 24th biggest position. Ameritas Investment Partners Inc.’s holdings in Eli Lilly and Company were worth $18,992,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Johnson Wealth Management LLC acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $253,000. Wellspring Financial Advisors LLC boosted its position in Eli Lilly and Company by 287.5% in the fourth quarter. Wellspring Financial Advisors LLC now owns 2,333 shares of the company’s stock valued at $2,509,000 after buying an additional 1,731 shares in the last quarter. Zions Bancorporation National Association UT boosted its position in Eli Lilly and Company by 10.2% in the fourth quarter. Zions Bancorporation National Association UT now owns 6,018 shares of the company’s stock valued at $6,467,000 after buying an additional 557 shares in the last quarter. J.Safra Asset Management Corp boosted its position in Eli Lilly and Company by 95.9% in the fourth quarter. J.Safra Asset Management Corp now owns 5,310 shares of the company’s stock valued at $5,706,000 after buying an additional 2,599 shares in the last quarter. Finally, GWN Securities Inc. boosted its position in Eli Lilly and Company by 7.6% in the fourth quarter. GWN Securities Inc. now owns 5,221 shares of the company’s stock valued at $5,612,000 after buying an additional 368 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA approved extended every-8-weeks maintenance dosing for EBGLYSS, improving convenience and potentially boosting adoption in Lilly’s dermatology business.
• Positive Sentiment: Reuters reported that Lilly is still viewed as the leader in the fast-growing obesity-drug market, even as rivals rush into the space, reinforcing confidence in its competitive moat. Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
• Positive Sentiment: Recent coverage also highlighted positive Phase 3 data for retatrutide and favorable Foundayo (orforglipron) weight-loss results, keeping investor enthusiasm high around Lilly’s obesity pipeline.
• Positive Sentiment: Jefferies raised its price target on LLY to $1,350 and reiterated a Buy rating, signaling continued analyst confidence in the stock’s runway. Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?
• Positive Sentiment: Lilly also announced a new Alzheimer’s collaboration with AlzeCure, expanding its neuroscience pipeline and adding another potential long-term growth opportunity.
• Neutral Sentiment: Several articles were commentary pieces or portfolio lists that reinforce Lilly’s reputation as a high-quality defensive growth name, but they do not add materially new fundamental information.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on LLY. Jefferies Financial Group raised their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday. CICC Research raised their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research report on Wednesday, February 11th. Bank of America lifted their price target on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Wolfe Research reiterated an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a report on Friday, May 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,227.74.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,138.78 on Thursday. The firm has a market cap of $1.07 trillion, a PE ratio of 40.45, a price-to-earnings-growth ratio of 1.25 and a beta of 0.53. The firm’s fifty day moving average is $989.96 and its 200-day moving average is $1,015.14. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,182.73.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.